Highbridge Capital Management, LLC filed Amendment No. 2 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of shares of Inovio Pharmaceuticals, Inc. common stock issuable upon exercise of warrants held by the Highbridge Funds.

Key Highlights

  • Reporting person: Highbridge Capital Management, LLC, a Delaware limited liability company and investment adviser to the Highbridge Funds.
  • Shares reported: 25,288,217 shares of common stock (par value $0.001 per share) issuable upon exercise of the Reported Warrants, reflecting sole voting and sole dispositive power.
  • Percent of class: 9.9%, calculated after giving effect to a 9.99% ownership blocker contained in the warrant terms.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Share base used: The percentage was calculated using 103,397,518 shares of common stock outstanding as of August 10, 2026, as reported in Inovio's quarterly filing for the period ended June 30, 2026.
  • Five-percent holder: Highbridge Tactical Credit Master Fund, L.P. has the right to receive or direct dividends or sale proceeds from more than 5% of the outstanding common stock, according to the filing.

Highbridge Warrant Position in Inovio and the 9.99% Ownership Cap

According to the filing, Highbridge Capital Management, LLC acts as investment adviser to certain funds and accounts collectively referred to as the Highbridge Funds, which directly hold the warrants underlying this disclosure. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a Plymouth Meeting, Pennsylvania-based biopharmaceutical company whose common stock carries a par value of $0.001 per share and is identified by CUSIP number 45773H409. The filing is classified as Amendment No. 2 to the original Schedule 13G.

The filing states that all 25,288,217 shares reported in rows 5, 7, and 9 of the cover page represent shares issuable upon full exercise of the Reported Warrants, and do not reflect the 9.99% Blocker. As a result, the filing notes, "the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of securities reported." Highbridge disclosed zero shared voting power and zero shared dispositive power, with all reported power held on a sole basis.

The filing further discloses that Highbridge Tactical Credit Master Fund, L.P., identified as one of the Highbridge Funds, holds the right to receive or direct more than 5% of Inovio's outstanding common stock from these securities. Highbridge certified that the securities were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of Inovio, as stated in the Item 10 certification signed by Kirk Rule, Executive Director, on November 16, 2026.

What Was Disclosed

Highbridge Capital Management, LLC filed Amendment No. 2 to its Schedule 13G disclosing a 9.9% beneficial ownership position in Inovio Pharmaceuticals, Inc., comprised entirely of shares issuable upon exercise of warrants held by the Highbridge Funds, subject to a 9.99% ownership blocker.